ClinicalTrials.gg
Active, not recruitingNCT04546620REMoDL-AUpdated Apr 30, 2026

Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)

A Phase 2 interventional study of R-CHOP and R-CHOP + acalabrutinib in Diffuse Large B Cell Lymphoma, sponsored by University Hospital Southampton NHS Foundation Trust. Active, not recruiting at 33 sites in United Kingdom. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by University Hospital Southampton NHS Foundation Trust · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
453
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies testing acalabrutinib in Lymphoma, Large B-Cell, Diffuse — 5 open to participants now, 12 under way, 2 of them phase 3. acalabrutinib · Lymphoma, Large B-Cell, Diffuse.

Planned enrollment
2nd of 15
453 · median 72
Started
2021
with 1 other
Phase 2
10 of 15
3 open now
Primary completion
2027-11
later than 6 of 11 live
Registered
7th of 15
by date

Among the 15 studies testing acalabrutinib in Lymphoma, Large B-Cell, Diffuse, this one is the 2nd largest by planned enrollment, is one of 2 that started in 2021, is one of 10 in phase 2, reaches primary completion later than 6 of the 11 other live ones, and was the 7th registered.

Lymphoma, Large B-Cell, Diffuse

1,873 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

5 of the 15 studies testing acalabrutinib in Lymphoma, Large B-Cell, Diffuse are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About acalabrutinib

acalabrutinib: first FDA approval 2017 (CALQUENCE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 265 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 176 (66%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing acalabrutinib in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

This study evaluates the addition of Acalabrutinib to current standard therapy of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) for patients with previously untreated CD20 positive Diffuse Large B-cell Lymphoma (DLBCL) requiring full course chemoimmunotherapy.

All patients will receive one cycle of R-CHOP. Two thirds of patients (Arm B) will go on to receive a further 5 cycles (every 21 days) of R-CHOP with Acalabrutinib. Acalabrutinib will be taken orally twice daily continuously in 21 day cycles.

One third of patients (Arm A) will continue with 5 cycles of R-CHOP.

Patients will be followed up initially for 24 months and then for disease status and survival until 114 progression events have been observed.

Read the detailed description

Diffuse large B-cell lymphoma (DLBCL) is the most common of the non-Hodgkin's lymphomas. Whilst the majority of patients will respond well to conventional treatment (R-CHOP - rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone), a significant number of patients lymphoma will not respond to initial therapy or their disease will return after completion of therapy. In a number of B-cell diseases an enzyme called, Bruton tyrosine kinase (BTK) prevents death of tumour cells, including in DLBCL. Acalabrutinib is an orally active BTK-inhibitor and it is thought that stopping BTK being activated may help in treating B-cell diseases. It is hypothesised that the addition of Acalabrutinib to standard R-CHOP immunochemotherapy may improve outcomes of patients with DLBCL.

REMoDL-A is a randomised, phase II, open label, multicentre study that will be open in up to 50 centres. Up to 553 patients (453 randomised) will be recruited.

Following informed consent all patients will receive 1 cycle of conventional R-CHOP chemotherapy. At the same time the diagnostic pathology block will be sent for molecular profiling by the Haematological Malignancy Diagnostic Service (HMDS). The delivery of the first cycle of R-CHOP will allow a sufficient interval for real time determination of molecular phenotype. Patients whose biopsies yield sufficient tumour material for profiling will be randomised 2:1 in favour of the experimental arm (R-CHOP + acalabrutinib).

The primary objective will be to establish if combining acalabrutinib with R-CHOP improves efficacy, compared to R-CHOP alone, for the treatment of previously untreated patients with DLBCL to a degree that justifies further development of this approach.

03

Conditions studied

  • Diffuse Large B Cell Lymphoma

Keywords

  • Lymphoma
  • Acalabrutinib
  • R-CHOP
  • DLBCL
  • Non Hodgkin Lymphoma
  • Haematological cancer
  • Bruton Tyrosine Kinase
  • Molecular Profiling
  • Chemoimmunotherapy
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed DLBCL, expressing CD20. Sufficient diagnostic material must be available to forward to HMDS for gene expression profiling and central pathology review. The following diagnoses by 2016 WHO classification of lymphoid neoplasms may be included:

    • DLBCL, not otherwise specified (NOS)
    • T-cell/histiocyte-rich large B-cell lymphoma
    • Epstein-Barr virus positive DLBCL, NOS
    • ALK-positive large B-cell lymphoma
    • HHV8-positive DLBCL, NOS
    • High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (double-hit or triple-hit lymphoma)
    • High-grade B-cell lymphoma, NOS
  • At least one bi-dimensionally , defined as >1.5 cm in its longest dimension as measured by CT.
  • Not previously treated for lymphoma and fit enough to receive combination chemoimmunotherapy with curative intent.
  • Stage IAX (bulk defined as lymph node mass [either single or conglomerate] diameter >7.5cm) to stage IV disease and deemed to require a full course of chemotherapy. Patients with non-bulky IE disease will not be eligible.
  • performance status 0-2 or 3 if this is directly attributable to lymphoma.
  • Adequate bone marrow function with > 100x109/L; neutrophils > 1.0x109/L at study entry, unless lower figures are attributable to lymphoma.
  • Measured or calculated > 30mls/min, (calculated using the formula of Cockcroft and Gault [(140-Age) x Mass (kg) x (1.04 (for women) or 1.23 (for men))/Serum Creatinine (μmolL)]).
  • Serum \< 35μmol/L and transaminases \< 1.5x at time of study entry.
  • Cardiac function sufficient to tolerate 300mg/m2 of doxorubicin. A pre-treatment echocardiogram or is required to establish baseline LVEF equal to or greater than institutional normal range.
  • No concurrent uncontrolled medical condition.
  • > 3 months.
  • Aged 16 years or above.
  • Willing and able to participate in all required evaluations and procedures in this study protocol including swallowing capsules without difficulty.
  • Ability to understand the purpose and risks of the study and provide signed and dated .

Exclusion criteria

Exclusion Criteria:

  • Previous history of treated or untreated indolent lymphoma. However newly diagnosed patients with DLBCL who are found to also have small cell infiltration of the bone marrow or other diagnostic material (discordant lymphoma) will be eligible.
  • Patients who have received immunisation with a within four weeks prior to enrolment will be ineligible.
  • Diagnosis of primary mediastinal lymphoma.
  • Diagnosis of primary Central Nervous System lymphoma or secondary CNS involvement. Those patients presenting with neurological symptoms should be investigated for CNS involvement. Routine CNS imaging or diagnostic lumbar puncture will not be required in the absence of symptoms.
  • History of stroke or intracranial haemorrhage in preceding 6 months.
  • History of bleeding diathesis (eg, haemophilia, von Willebrand disease).
  • History of drug-specific or anaphylaxis to any study drug (including active product or components).
  • Requires or receiving anticoagulation with warfarin or equivalent antagonists (eg, phenprocoumon) within 7 days of first dose of acalabrutinib. However patients using therapeutic low molecule weight heparin or low dose aspirin will be eligible as will those receiving direct oral anticoagulants.
  • Prior exposure to an inhibitor in the BCR pathway (eg, Btk inhibitors, phosphoinositide-3 kinase (PI3K), or Syk inhibitors) or BCL-2 inhibitor (eg, ABT-199).
  • Requires treatment with a strong cytochrome P450 3A4 () inhibitor/inducer.
  • Requires treatment with proton pump inhibitors (eg, omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole). Patients receiving proton pump inhibitors should switch to short-acting H2-receptor antagonists or antacids prior to the commencement of acalabrutinib, if randomised to receive acalabrutinib.
  • Active significant infection (e.g. progressive multifocal leukoencephalopathy (PML)).
  • Uncontrolled haemolytic anaemia (AIHA) or idiopathic thrombocytopenic purpura (ITP).
  • Major surgery in the preceding 4 weeks of first dose of acalabrutinib (if applicable). If a subject had major surgery, they must have recovered adequately from any toxicity and/or complications from the intervention before the first dose of acalabrutinib (if applicable).
  • use >30 mg/day of prednisone or equivalent, for purposes other than for lymphoma symptom control. Patients receiving corticosteroid treatment with \<30 mg/day of prednisone or equivalent must be documented to be on a stable dose of at least 4 weeks' duration prior to the start of Cycle 1. If glucocorticoid treatment is urgently required for lymphoma symptom control prior to the start of study treatment, prednisone 100 mg or equivalent could be given for a maximum of 14 days as a prephase. A dose of up to 30mg or prednisolone or equivalent may be used during the screening phase to control symptoms.
  • Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 or 4 cardiac disease as defined by the Functional Classification.
  • Serological positivity for , C, or known infection. As per standard of care, prior to initiation of immunochemotherapy, the results of hepatitis serology should be known prior to commencement of therapy.

    1. Positive test results for chronic HBV infection (defined as positive HBsAg serology) will not be eligible. Patients with occult or prior HBV infection (defined as negative HBsAg and positive total HBcAb) will not be eligible. Patients who have protective titres of hepatitis B surface antibody (HBsAb) after vaccination will be eligible.
    2. Patients positive for antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.
  • Women who can bear children must agree to use two highly effective forms of or abstinence during the study and for 12 months after the last treatment dose.
  • Breastfeeding or pregnant women.
  • Men who can father children must agree to use two highly effective forms of contraception with additional barrier or abstinence during the study and for 12 months after the last treatment dose.
  • Men must agree to refrain from sperm donation during the study and for 12 months after the last treatment dose.
  • Serious medical or psychiatric illness likely to affect participation or that may compromise the ability to give .
  • Prior (other than DLBCL), except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease free for ≥ 2 years or which will not limit survival to \< 2 years.
  • Has difficulty with or is unable to swallow oral medication, or has significant gastrointestinal disease, resection of the stomach or small bowel, partial or complete bowel obstruction or gastric restrictions and bariatric surgery, such as gastric bypass that would limit absorption of oral medication.
  • Any immunotherapy within 4 weeks of 1st dose of the study.
  • Concurrent participation in another therapeutic clinical trial.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
453 participants (estimated)

Study arms

  • Active comparator
    Arm A Control

    6 cycles of standard R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) immunochemotherapy every 21 days.

    Drug: R-CHOP

  • Experimental
    Arm B Experimental

    1 cycle of standard R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) immunochemotherapy followed by 5 cycles of R-CHOP + acalabrutinib taken twice daily for 21 day cycles.

    Drug: R-CHOP + acalabrutinib

Interventions

  • DrugR-CHOP

    Arm A patients will receive R-CHOP alone.

    Also known as: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone

  • DrugR-CHOP + acalabrutinib

    Drug page: AcalabrutinibStudies of AcalabrutinibAcalabrutinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Arm B patients will receive R-CHOP in combination with acalabrutinib.

    Also known as: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, Acalabrutinib

06

What researchers measure

Primary outcomes

  1. To establish if combining acalabrutinib with R-CHOP improves efficacy, compared to RCHOP alone, for the treatment of previously untreated patients with DLBCL to a degree that justifies further development of this approach.

    Progression-free survival (PFS) is defined as time from registration to progression/death from any cause.

    Time frame: Last patient's last follow up, approximately 4.5 years. Patients who do not experience a PFS event will be censored at the date of last follow up.

Secondary outcomes

  1. To compare PFS between molecular groups.

    PFS interaction with cell of origin phenotype (ABC, GCB and unclassifiable).

    Time frame: Last patient's last follow-up, approximately 4.5 years.

  2. To compare PFS between treatment groups.

    PFS interaction with clinical variables, including for example IPI, bulk, components of IPI, age and others to be determined in the SAP.

    Time frame: Last patient's last follow-up, approximately 4.5 years.

  3. To compare overall survival (OS) between both treatment and molecular groups.

    Overall survival (OS), defined as time from registration to death from any cause.

    Time frame: Last patient's last follow-up, approximately 4.5 years. Patients who do not experience an OS event will be censored at the date of last follow-up.

  4. To compare event free survival (EFS) between both treatment and molecular groups.

    Event-free survival (EFS), or time to treatment failure, defined as time from registration to any treatment failure including disease progression, or discontinuation of treatment for any reason.

    Time frame: Last patient's last follow-up, approximately 4.5 years. Patients who do not experience an EFS event will be censored at the date of last follow-up.

  5. To compare disease free survival (DFS) between both treatment and molecular groups.

    Disease-free survival (DFS), defined as time of documentation of disease-free state to disease recurrence or death as a result of lymphoma or acute toxicity of treatment.

    Time frame: Last patient's last follow-up, approximately 4.5 years. Patients who do not experience a DFS event will be censored at the date of last follow-up.

  6. To compare time to progression (TTP) between both treatment and molecular groups.

    Time to progression (TTP), defined as time from registration until documented lymphoma progression or death as a result of lymphoma. Deaths from other causes are censored at the time of death.

    Time frame: Last patient's last follow-up, approximately 4.5 years. Patients who do not experience a TTP event will be censored at the date of last follow-up.

  7. To compare duration of response (DoR) between both treatment and molecular groups.

    Response duration (DoR), defined as the time from documentation of response until the documentation of relapse or progression.

    Time frame: Last patient's last follow-up, approximately 4.5 years. Patients who do not experience a RD event will be censored at the date of last follow-up.

  8. To compare overall response rate (ORR) and complete response rate (CR) between both treatment groups.

    Assessment using the Lugano Response Criteria for Malignant Lymphoma.

    Time frame: Complete and overall response rates, as recorded at the end of treatment (up to 21 weeks) .

  9. To assess differences in toxicity between assigned treatments.

    Evaluation of toxicity according to CTCAE version 5.

    Time frame: At all visits up to 24 months follow-up.

  10. To assess differences in quality of life between treatment arms.

    Application of the EORTC QLQ-C30 and FACT-Lym questionnaires.

    Time frame: At baseline, cycle 2 day 1, cycle 3 day 1, cycle 5 day 1, end of treatment and at 3, 6, 12, 20 and 24 month follow-ups. Each cycle is 21 days.

Other outcomes

  1. To explore correlation of molecular characteristics in tumour material to clinical outcomes.

    Applying the following techniques to FFPE tumour material: mutational panel, FISH analysis, immunohistochemical analysis for dual protein expression of Myc and Bcl2 and dynamic changes in ctDNA and methylation based ctDNA during treatment and follow up.

    Time frame: At baseline, cycle 2 day 1, cycle 3 day 1, end of treatment and at 3, 6, 9 and 12 month follow-ups. Each cycle is 21 days.

  2. To explore correlation of baseline PET features including tumour burden and bone marrow involvement to clinical outcomes.

    Tumour burden defined by metabolic tumour volume (MTV) and tumour lesion glycolysis (TLG). Bone marrow involvement defined by focal uptake in the bone marrow higher than liver uptake; diffuse bone marrow uptake higher than liver uptake will be recorded and correlated with bone marrow biopsy results where available (number and location of extranodal sites).

    Time frame: Baseline and end of treatment (up to 21 weeks).

  3. To explore combination(s) of clinical risk factors, molecular characteristics and PET features to clinical outcomes.

    Time frame: Baseline and end of treatment (up to 21 weeks).

  4. To compare metabolic response between molecular groups.

    Time frame: Baseline and end of treatment (up to 21 weeks).

  5. To update existing metabolic response criteria using advanced PET reconstructions.

    Time frame: Baseline and end of treatment (up to 21 weeks).

07

Study locations

33 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2021 (actual). Primary completion is estimated for Nov 2027, 73 months after the start.

Of 211 non-industry phase 2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 96. This study's planned 73 months is above that.

Counting every sponsor, half of 264 studies reached it within 52 months; a quarter within 35 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2020
First posted
Sep 14, 2020
StartActual
Oct 19, 2021
Primary completionEst.
Nov 2027
CompletionEst.
May 2028
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04546620
Collaborators
AstraZeneca
Responsible party
Sponsor
First posted
Sep 14, 2020
Start date
Oct 19, 2021
Primary completion
Nov 2027 (estimated)
Completion
May 2028 (estimated)
Last update
Apr 30, 2026

Study contacts

Andrew Davies
principal investigator · University of Southampton

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acalabrutinib

Start the discussion